PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer.

Pantelidou, Constantia; Sonzogni, Olmo; de Oliveira Taveira, Mateus; Mehta, Anita K; Kothari, Aditi; Wang, Dan; Visal, Tanvi; Li, Michelle K; Pinto, Jocelin; Castrillon, Jessica A; Cheney, Emily M; Bouwman, Peter; Jonkers, Jos; Rottenberg, Sven; Guerriero, Jennifer L; Wulf, Gerburg M; Shapiro, Geoffrey I (2019). PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer discovery, 9(6), pp. 722-737. American Association for Cancer Research 10.1158/2159-8290.CD-18-1218

Preview	Text Pantelidou et al.Composite Manuscript.9April2019.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview
	Text 722.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (10MB)

Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We demonstrate that the PARP inhibitor olaparib induces CD8+ T cell infiltration and activation in vivo, and that CD8+ T cell depletion severely compromises anti-tumor efficacy. Olaparib-induced T cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared to HR-proficient TNBC cells and in vivo models. CRISPR-knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T cell infiltration in vivo. These findings elucidate an additional mechanism of action of PARP inhibitors and provide rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC.

Interest & Impact

Downloads

895 since deposited on 05 Jun 2019
58 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item